Carboplatin News and Research

RSS
Carboplatin is a chemotherapy drug used against some forms of cancer (mainly ovarian carcinoma, lung, head and neck cancers).
Two genomic tests help identify most effective treatment for breast cancer patients

Two genomic tests help identify most effective treatment for breast cancer patients

U.S. Department of Defense grants 'Impact Award' to explore therapeutic options against advanced prostate cancer

U.S. Department of Defense grants 'Impact Award' to explore therapeutic options against advanced prostate cancer

Immunotherapy with pembrolizumab extends survival in metastatic or recurrent head and neck cancer

Immunotherapy with pembrolizumab extends survival in metastatic or recurrent head and neck cancer

Study findings could set new standard of care for advanced anal cancer

Study findings could set new standard of care for advanced anal cancer

Genentech’s combination therapy improves outcome in patients with non-squamous non-small cell lung cancer

Genentech’s combination therapy improves outcome in patients with non-squamous non-small cell lung cancer

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

ImmunoGen announces study results of platinum-resistant ovarian cancer therapy at ESMO 2018 Congress

ImmunoGen announces study results of platinum-resistant ovarian cancer therapy at ESMO 2018 Congress

Finding which chemotherapy regimen is associated with best outcomes for patients with bladder cancer

Finding which chemotherapy regimen is associated with best outcomes for patients with bladder cancer

European Commission approves Pfizer’s first oncology biosimilar

European Commission approves Pfizer’s first oncology biosimilar

CNDA approves KEYTRUDA for treatment of advanced melanoma

CNDA approves KEYTRUDA for treatment of advanced melanoma

Phase 3 study of KEYTRUDA monotherapy meets primary endpoint

Phase 3 study of KEYTRUDA monotherapy meets primary endpoint

Merck announces FDA acceptance of supplemental Biologics License Application for KEYTRUDA

Merck announces FDA acceptance of supplemental Biologics License Application for KEYTRUDA

Neon Therapeutics evaluates safety, efficacy of NEO-PV-01 in combination with KEYTRUDA and chemotherapy

Neon Therapeutics evaluates safety, efficacy of NEO-PV-01 in combination with KEYTRUDA and chemotherapy

Experimental diabetes drugs can make cancer cells vulnerable to chemotherapy agents

Experimental diabetes drugs can make cancer cells vulnerable to chemotherapy agents

New first line combination therapy shows promising results in patients with advanced NSCLC

New first line combination therapy shows promising results in patients with advanced NSCLC

Genome-wide molecular tests can guide treatment in recurrent glioblastoma, study shows

Genome-wide molecular tests can guide treatment in recurrent glioblastoma, study shows

FDA grants approval for new biosimilar to treat multiple types of cancer

FDA grants approval for new biosimilar to treat multiple types of cancer

Study: Chemoradiation should remain standard treatment for locally advanced cervical cancer

Study: Chemoradiation should remain standard treatment for locally advanced cervical cancer

Trial confirms standard three-week dosing of chemotherapy as first line treatment in ovarian cancer

Trial confirms standard three-week dosing of chemotherapy as first line treatment in ovarian cancer